StaffDecember 17, 2020
Zelira Therapeutics Ltd (ASX:ZLD, OTCQB:ZLDAF), a leader in cannabis research and the development of clinically validated cannabis medicines, just announced its newest licensing agreement for its HOPE™ line of products, Zelira’s top-selling treatment developed for autism patients. Under the agreement with Alternative Solutions, a licensed grower, manufacturer and distributor of medical cannabis products in the District of Columbia (Washington DC), HOPE™ will be produced and distributed throughout the legal DC medical cannabis market beginning in Q2 2021.
“We are thrilled to have Alternative Solutions as a partner to launch HOPE™ in the nation’s capital,” says Dr. Oludare Odumosu, CEO & Managing Director USA for Zelira. “They are a leader in the DC medical cannabis market, and this partnership will allow legal access of HOPE™ to more patients across the country than ever before.”
Odumosu notes that this agreement with Alternative Solutions signifies HOPE’s largest expansion to date; because Washington DC has reciprocity with 32 other states in the US with approved medical cannabis programs, patients registered in those states are able to legally purchase medical cannabis products at an approved dispensary in Washington DC.
HOPE™ was formulated by Zelira Therapeutics and is the brainchild of Erica Daniels, founder of Hope Grows for Autism, a nonprofit aimed at improving the lives of families affected by autism through research, education and advocacy of medical marijuana. HOPE™ is currently available in the United States in Pennsylvania, through an exclusive license agreement with Ilera Healthcare, and in Louisiana, through an agreement with Advanced Biomedics LLC.
